Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial - Fitzgerald, Kevin; Frank-Kamenetsky, Maria; Shulga-Morskaya, Svetlana; Liebow, Abigail; Bettencourt, Brian R; Sutherland, Jessica E; Hutabarat, Renta M; Clausen, Valerie A; Karsten, Verena; Cehelsky, Jeffrey; Nochur, Saraswathy V; Kotelianski, Victor; et al. (The Lancet (British edition), 2014)
Keywords: Adult; Biological and medical sciences; Cardiovascular disease; Cardiovascular diseases; Cholesterol; Cholesterol, LDL - blood; Cholesterol, LDL - drug effects; Dose-Response Relationship, Drug; Drug dosages; Female; General aspects; Genetic Therapy - adverse effects; Genetic Therapy - methods; Genetics; Healthy Volunteers; Heart; Humans; Internal Medicine; Lipids; Male; Medical sciences; Middle Aged; Mutation; Nanoparticles; Nutrition research; Pharmacokinetics; Plasma; Proprotein Convertase 9; Proprotein Convertases - biosynthesis; Proprotein Convertases - blood; Proprotein Convertases - genetics; RNA Interference; RNA, Small Interfering - administration & dosage; RNA, Small Interfering - adverse effects; RNA, Small Interfering - pharmacology; Serine Endopeptidases - biosynthesis; Serine Endopeptidases - blood; Serine Endopeptidases - genetics; Single-Blind Method; Statins; Studies; Drug; RNA interference; Serine endopeptidases; Healthy subject; Enzyme; Cholesterol LDL; Subtilisin; Concentration; Medicine; Peptidases; Gene silencing; Randomization; Kexin; RNA synthesis; Placebo; Phase I trial; Hydrolases; Clinical trial; Serum